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Indoleamine 2,3-dioxygenase 1 (IDO1) degrades trypto-
phan into kynurenine (KYN) and other immune suppres-
sive molecules that inhibit effector T cells and promote
regulatory T-cell differentiation. We have previously
shown that IDO1 mRNA and protein are detectable in
blast cells from 52% of adults with newly diagnosed acute
myeloid leukemia (AML). Herein, we investigated IDO1
expression and function in 41 children with AML (median
age=10 years, range 1-17). In 20/41 cases, leukemia blast
cells up-regulated IDO1 after in vitro challenge with
IFN-g. Of interest, microenvironmental IFN-g was higher
in IDO(pos) compared with IDO(neg) patients. In line
with these results, bone marrow (BM)-resident T cells
produced more IFN-g, but not IL-4 or IL-17, compared
with T cells from normal BM samples. KYN levels signifi-
cantly increased in supernatants of IFN-g-stimulated AML
cells (21.0 μM/L, range 6.1-36.0) compared with unstimu-
lated cultures (0.85 μM/L, range 0.4-1.7; p=0.0022), in
parallel with tryptophan consumption (2.95 μM/L, range
1.0-37.0, after challenge with IFN-g compared with 38.1
μM, range 18.2-50.0, in unstimulated cultures; p<0.0001).
In a mixed tumor cell lymphocyte culture, AML blasts
primed with IFN-g inhibited Th1 cytokine production by
allogeneic CD8+ and, to a lesser extent, CD4+ T cells,
while enhancing Th2 cytokine release. The provision of D,
L-1-methyl-tryptophan (1MT), an IDO inhibitor, to
T-cell/AML co-cultures partially restored IFN-g produc-
tion by both CD4+ and CD8+ T cells. Furthermore,
IDO-expressing AML blasts inhibited NK-cell degranula-
tion, as measured through CD107a expression. Finally, 5-
year overall survival was significantly better for IDO(neg)
patients (34 months) compared with IDO(pos) ones (64.7
months; p=0.0438; Figure 1). In conclusion, IDO sup-
presses Th1 responses/NK activity and may portend an
unfavorable prognosis in childhood AML.
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Figure 1 The 5-year overall survival of IDO-positive and IDO-
negative patients with AML is shown.
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